Equibles does not estimate personal net worth.
Get an email with a short summary when SAB Biotherapeutics, Inc. publishes a filing, an earnings call transcript or a press release.
Get SABS alertsLucy To is recorded as CFO at SAB Biotherapeutics, Inc. (SABS). The newest filing on record that lists Lucy To as CFO at SAB Biotherapeutics, Inc. (SABS) is dated April 30, 2026. SAB Biotherapeutics, Inc. reported in an 8-K filed July 31, 2024 that Lucy To was appointed Chief Financial Officer, effective August 12, 2024. Lucy To has spoken on 1 earnings call across 1 company, most recently for SAB Biotherapeutics, Inc. on August 6, 2026. SAB Biotherapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at SAB Biotherapeutics, Inc. includes Samuel J. Reich (CEO and Board Member), David Zaccardelli (Chairman and Board Member), Mark Conley (CFO) and 7 others.
“On July 26, 2024, Lucy To, 38, was appointed Chief Financial Officer of SAB Biotherapeutics, Inc., a Delaware corporation (“SAB BIO” or the “Company”), with a start date of August 12, 2024.”
“We ended the quarter with $208 million in cash, cash equivalents, and investment securities as of June 30, 2026. We continue to have a strong cash position with operational runway through 2028.”
Start not stated–present
Last confirmed April 30, 2026
Biotechnology · Healthcare
CFO
